deltatrials
Recruiting PHASE2 INTERVENTIONAL 1-arm NCT03152058

IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

Certolizumab to Prevent Pregnancy Complications in High-Risk Patients With APS or SLE - (IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy)

Sponsor: David Ware Branch

Conditions Antiphospholipid Syndrome in Pregnancy High Risk Pregnancy Lupus Anticoagulant Disorder Pregnancy Complications
Interventions Certolizumab Pegol
Updated 16 times since 2017 Last updated: Dec 5, 2024 Started: May 17, 2017 Primary completion: Dec 31, 2025 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Antiphospholipid Syndrome in Pregnancy and High Risk Pregnancy and is currently actively recruiting participants. David Ware Branch leads this study, which shows 16 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jun 2017 – ~Jun 2018 · 12 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Apr 2019 · 8 months · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Apr 2020 · 10 months · monthly snapshot~Apr 2020 – ~Dec 2020 · 8 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Jun 2022 · 13 months · monthly snapshot~Jun 2022 – ~Jun 2023 · 12 months · monthly snapshot~Jun 2023 – ~Nov 2023 · 5 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – present · 18 months · monthly snapshot

Change History

16 versions recorded

  1. Jan 2025 — Present [monthly]

    Recruiting PHASE2

  2. Sep 2024 — Jan 2025 [monthly]

    Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  4. Nov 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

  5. Jun 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

▶ Show 11 earlier versions

  1. Jun 2022 — Jun 2023 [monthly]

    Recruiting PHASE2

  2. May 2021 — Jun 2022 [monthly]

    Recruiting PHASE2

  3. Jan 2021 — May 2021 [monthly]

    Recruiting PHASE2

  4. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  5. Apr 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

  6. Jun 2019 — Apr 2020 [monthly]

    Recruiting PHASE2

  7. Apr 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  8. Aug 2018 — Apr 2019 [monthly]

    Recruiting PHASE2

  9. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  10. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  11. Jun 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    First recorded

May 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • David Ware Branch
  • Hospital for Special Surgery, New York
  • NYU Langone Health
  • University of Toronto
Data source: University of Utah

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations